We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Becton, Dickinson (BDX) Q3 Earnings: What's in the Cards?
Read MoreHide Full Article
Becton, Dickinson and Company (BDX - Free Report) is set to report third-quarter fiscal 2016 earnings results on Aug 4. Last quarter, Becton, Dickinson beat the Zacks Consensus Estimate by almost 8.5% (17 cents).
We note that on average, the company delivered a positive earnings surprise of 5.04% through the last four quarters.
Let’s see how things are shaping up prior to this announcement.
Factors at Play
Becton, Dickinson's innovative product pipeline is a key catalyst in our view. A plethora of regulatory approvals both in the U.S. and International markets is aiding the company to rapidly expand its product portfolio.
Management at Becton, Dickinson expects strong demand for its Pyxis ES platform and infusion pumps to be the primary growth drivers in the third quarter.
Additionally, partnerships and collaborations are also providing the company a competitive edge. Moreover, the CareFusion merger has unlocked considerable growth and cost saving opportunities for Becton, Dickinson.
However, unfavorable foreign exchange rate is anticipated to remain a headwind for the rest of year. Tough year-over-year comparisons in the third quarter also remain a concern.
Earnings Whispers
Our proven model does not conclusively show that Becton, Dickinson is likely to beat on earnings this quarter. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank of #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. That is not the case here as you will see below.
Zacks ESP: Becton, Dickinson currently has an Earnings ESP of 0.00%. This is because both the Most Accurate estimate and the Zacks Consensus Estimate stand at $2.20.
Zacks Rank: Becton, Dickinson has a Zacks Rank #3 which increases the predictive power of ESP. However, a 0.00% ESP makes surprise prediction difficult.
We caution against stocks with a Zacks Rank #4 or 5 (Sell rated) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks to Consider
Here are some companies you may want to consider as our model shows they have the right combination of elements to post an earnings beat this quarter:
Nektar Therapeutics (NKTR - Free Report) with an Earnings ESP of +50.00% and Zacks Rank #1.
GlycoMimetics Inc. (GLYC - Free Report) with an Earnings ESP of +13.64% and Zacks Rank #1.
ANI Pharmaceuticals Inc. (ANIP - Free Report) with an Earnings ESP of +2.63% and a Zacks Rank #1.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Becton, Dickinson (BDX) Q3 Earnings: What's in the Cards?
Becton, Dickinson and Company (BDX - Free Report) is set to report third-quarter fiscal 2016 earnings results on Aug 4. Last quarter, Becton, Dickinson beat the Zacks Consensus Estimate by almost 8.5% (17 cents).
We note that on average, the company delivered a positive earnings surprise of 5.04% through the last four quarters.
Let’s see how things are shaping up prior to this announcement.
Factors at Play
Becton, Dickinson's innovative product pipeline is a key catalyst in our view. A plethora of regulatory approvals both in the U.S. and International markets is aiding the company to rapidly expand its product portfolio.
BECTON DICKINSO Price and EPS Surprise
BECTON DICKINSO Price and EPS Surprise | BECTON DICKINSO Quote
Management at Becton, Dickinson expects strong demand for its Pyxis ES platform and infusion pumps to be the primary growth drivers in the third quarter.
Additionally, partnerships and collaborations are also providing the company a competitive edge. Moreover, the CareFusion merger has unlocked considerable growth and cost saving opportunities for Becton, Dickinson.
However, unfavorable foreign exchange rate is anticipated to remain a headwind for the rest of year. Tough year-over-year comparisons in the third quarter also remain a concern.
Earnings Whispers
Our proven model does not conclusively show that Becton, Dickinson is likely to beat on earnings this quarter. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank of #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. That is not the case here as you will see below.
Zacks ESP: Becton, Dickinson currently has an Earnings ESP of 0.00%. This is because both the Most Accurate estimate and the Zacks Consensus Estimate stand at $2.20.
Zacks Rank: Becton, Dickinson has a Zacks Rank #3 which increases the predictive power of ESP. However, a 0.00% ESP makes surprise prediction difficult.
We caution against stocks with a Zacks Rank #4 or 5 (Sell rated) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks to Consider
Here are some companies you may want to consider as our model shows they have the right combination of elements to post an earnings beat this quarter:
Nektar Therapeutics (NKTR - Free Report) with an Earnings ESP of +50.00% and Zacks Rank #1.
GlycoMimetics Inc. (GLYC - Free Report) with an Earnings ESP of +13.64% and Zacks Rank #1.
ANI Pharmaceuticals Inc. (ANIP - Free Report) with an Earnings ESP of +2.63% and a Zacks Rank #1.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>